Clinical Trials
Clinical trials are essential to developing new treatments for the diseases that cause dementia, and to ensuring that these are safe and effective.
For people in the UK to be among the first to benefit from new treatments the UK needs to be a leading location for clinical trials. This is dependent on a number of factors including investment in research and the clinical trials infrastructure and how easy it is for pharmaceutical companies to conduct trials and for new treatments to be approved for use in the healthcare system.
ARUK report: The Economic Value of Dementia Research.
ARUK report: The Economic Value of Dementia Research.
Number of participants recruited to NIHR phase 3 trials over 10 years
clinical trials
participation
compare, comparison
cancer
phase 3
Parliamentary question for the Department of Health and Social Care.
Involvement in phase 3 clinical trials by country
clinical trials
global
worldwide
phase 3